Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2018-03354 | Registry Identifier | CTRP (Clinical Trial Reporting Program) | |
| 2018-0794 | Other Identifier | M D Anderson Cancer Center | |
| U01DA047875 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
This early phase I trial studies potential differences between men and women when switching from the use of combustible cigarettes to the National Institute on Drug Abuse's Standard Research E-Cigarette (SREC). Studying the differences between men and women may increase understanding about the effects of switching from smoking regular cigarettes to electronic cigarettes.
PRIMARY OBJECTIVES:
I. To characterize the effects of switching to nicotine versus (vs.) placebo standard research E-cigarettes (SRECs) from combustible cigarettes (CCs) on product use, product acceptability, reinforcement, and nicotine dependence symptoms among adult daily CC smokers.
II. To characterize the differences between male and female CC smokers when switching to nicotine versus (vs.) placebo SRECs from CCs on product use, product acceptability, reinforcement, and nicotine dependence symptoms.
EXPLORATORY OBJECTIVE:
I. To characterize which factors moderate or mediate the effects of switching to nicotine and placebo SRECs from CCs among male and female CC smokers.
OUTLINE:
Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| E-Cig placebo dose followed by E-Cig nicotine dose | Experimental | Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation. |
|
| E-Cig nicotine dose followed by E-Cig placebo dose | Experimental | Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nicotine Replacement | Drug | Received NRT (Electronic Cigarette - With Nicotine) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cigarettes Per Day | Mean cigarettes per day (CPD) smoked during the phase | 2 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Electronic Cigarette Sessions Per Day | Study electronic cigarette use measured by the mean number of sessions per day during each phase for male and female participants. | 2 weeks |
| Total Nicotine Equivalents (TNE) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jason Robinson | M.D. Anderson Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41051837 | Derived | Robinson JD, Cui Y, Karam-Hage M, Blalock JA, Shete S, Kypriotakis G, Yang P, Cinciripini PM. Standardized research electronic cigarette acceptability among adult men and women who smoke combustible cigarettes. Psychol Addict Behav. 2025 Dec;39(8):780-791. doi: 10.1037/adb0001100. Epub 2025 Oct 6. |
| Label | URL |
|---|---|
| MD Anderson Cancer Center | View source |
Not provided
Of the 1363 potential participants who responded to study advertising, 702 were screened for interest and eligibility. Of those screened, 130 were ineligible and 402 declined to participate. A total of 169 participants were randomized.
Participants were adult individuals residing in the state of Texas who completed the study remotely.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Phase 1: Usual Brand Cigarette Phase (Men) | Two weeks (Phase 1; weeks 1-2) of smoking usual brand cigarettes (men) |
| FG001 | Phase 1: Usual Brand Cigarette Phase (Women) | Two weeks (Phase 1; weeks 1-2) of smoking usual brand cigarettes (women) |
| FG002 | Phase 2 Placebo, Then Phase 3 Standardized Research Electronic Cigarette (SREC) (Men) | Two weeks (Phase 2; weeks 3-4) of placebo Standardized Research Electronic Cigarette use, followed by two weeks (Phase 3; weeks 5-6) of nicotine Standardized Research Electronic Cigarette use (Men) |
| FG003 | Phase 2 Placebo, Then Phase 3 SREC (Women) | Two weeks (Phase 2; weeks 3-4) of placebo Standardized Research Electronic Cigarette use, followed by two weeks (Phase 3; weeks 5-6) of nicotine Standardized Research Electronic Cigarette use (Women) |
| FG004 | Phase 2 SREC, Then Phase 3 Placebo (Men) | Two weeks (Phase 2; weeks 3-4) of nicotine Standardized Research Electronic Cigarette use, followed by two weeks (Phase 3; weeks 5-6) of placebo Standardized Research Electronic Cigarette use (Men) |
| FG005 | Phase 2 SREC, Then Phase 3 Placebo (Women) | Two weeks (Phase 2; weeks 3-4) of nicotine Standardized Research Electronic Cigarette use, followed by two weeks (Phase 3; weeks 5-6) of placebo Standardized Research Electronic Cigarette use (Women) |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1: Week 1-2 |
| |||||||||||||
| Phase 2: Week 3-4 |
| |||||||||||||
| Phase 3: Week 5-6 |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Phase 1: Usual Brand Cigarette Phase (Men) | Two weeks of smoking usual brand cigarettes followed by two weeks of using the Placebo (0% nicotine content) Standardized Research Electronic Cigarette (SREC) and the two weeks of using the Nicotine (5% nicotine content) SREC, with SREC order counterbalanced. |
| BG001 |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Cigarettes Per Day | Mean cigarettes per day (CPD) smoked during the phase | Posted | Mean | Standard Deviation | Cigarettes per Day | 2 weeks |
|
10 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Usual Brand Cigarette Phase (Men) | Two weeks of smoking usual brand cigarettes (Men) |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal Pain | Gastrointestinal disorders | Systematic Assessment |
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Jason Robinson | M.D. Anderson Cancer Center | 713-792-2265 | nicotinestudy@mdanderson.org |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Feb 10, 2025 | Mar 25, 2025 | Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Dec 6, 2022 | Jan 9, 2026 | ICF_001.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000095488 | Nicotine Replacement Therapy |
| ID | Term |
|---|---|
| D004358 | Drug Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Questionnaire Administration | Other | Ancillary studies |
|
| Electronic Cigarette | Device | Electronic Cigarette - with Nicotine |
|
| Electronic Cigarette | Device | Electronic Cigarette -without Nicotine |
|
A measure of nicotine exposure, calculated as the sum of total nicotine, cotinine, 3'-hydroxycotinine, and nicotine N-oxide excreted in urine, collected at the end of each phase for male and female participants.
| 2 weeks |
| Anabasine | A tobacco minor alkaloid (MA) excreted in urine collected at the end of each phase for male and female participants to evaluate nicotine product exposure. | 2 weeks |
| Nicotelline | A tobacco minor alkaloid (MA) excreted in urine collected at the end of each phase for male and female participants to evaluate nicotine product exposure. | 2 weeks |
| Perceived Health Risk Questionnaire (PHRQ) | Evaluation of participants' beliefs about their risks of developing health conditions from cigarettes or electronic cigarette collected at the end of each phase for male and female participants. Range 1-10, with higher values indicating greater perceived risk of negative health outcomes. | 2 weeks |
| Product Evaluation Scales (PES) | Evaluation of explicit cigarette or electronic cigarette product liking collected at the end of each phase for male and female participants. Range 1-7, with higher values indicating more unpleasant ratings. | 2 weeks |
| Implicit Association Test (IAT) | Evaluation of implicit cigarette or electronic cigarette liking collected at the end of each phase for male and female participants. Range: -1 to 1, with more negative values indicating a more negative attitude toward the cigarette product | 2 weeks |
| Brief Smoking Consequences Questionnaire-Adult (BSCQ-A) | Evaluation of the perceived outcomes of cigarette or electronic cigarette use collected at the end of each phase for male and female participants. Range 0 to 9, with larger values indicating greater perceived negative consequences of cigarette use | 2 weeks |
| Purchase Task Breakpoint Measure | Evaluation of the Purchase Task Breakpoint measure (first price at which consumption goes to zero, i.e., unwilling to pay) for cigarettes or electronic cigarettes collected at the end of each phase for male and female participants. Range: 0.05 - 251, dollars per cigarette or per electronic cigarette puff with higher values indicating the willingness to smoke/vape at a higher price. | 2 weeks |
| Purchase Task Demand Intensity Measure | Evaluation of the Purchase Task Demand Intensity measure (consumption at the lowest price) for cigarettes or electronic cigarettes collected at the end of each phase for male and female participants. Range: 1 - 351, the number of cigarettes or electronic cigarette puffs with higher values indicating an intension to smoke/vape more when the price is set as 0 | 2 weeks |
| Purchase Task Omax Measure | Evaluation of the Purchase Task Omax measure (maximum financial expenditure on the product) for cigarettes or electronic cigarettes collected at the end of each phase for male and female participants. Range: 0.03 - 1001, the maximum expenditure in dollars on cigarettes or electronic cigarette puffs with higher values indicating greater expenditure | 2 weeks |
| Purchase Task Pmax Measure | Evaluation of the Purchase Task Pmax measure (price at which expenditure is maximized) for cigarettes or electronic cigarettes collected at the end of each phase for male and female participants. Range: 0.01 - 1001, the price of the cigarette or electronic cigarette puffs when the Omax is reached | 2 weeks |
| Purchase Task Elasticity of Demand Measure | Evaluation of the Purchase Task Elasticity of Demand measure (sensitivity of product consumption to increases in cost) for cigarettes or electronic cigarettes collected at the end of each phase for male and female participants. Range: 0.0001 - 2.69, the elasticity of the demand for cigarettes or electronic cigarette puffs, with higher values indicating a greater sensitivity in reducing the consumption in response to the price increases | 2 weeks |
| Fagerström Test for Cigarette Dependence (FTCD) | Evaluation of cigarette dependence collected at the end of each phase for male and female participants. Range 0 to 10, with higher values indicating greater cigarette dependence | 2 weeks |
| Penn State Electronic Cigarette Dependence Index (PSECDI) | Evaluation of electronic cigarette dependence collected at the end of each phase for male and female participants. Range 0 to 20, with higher scores indicating greater electronic cigarette dependence | 2 weeks |
| Minnesota Nicotine Withdrawal Scale-Revised (MNWS) | Evaluation of nicotine withdrawal symptoms collected at the end of each phase for male and female participants. Range 0 to 60, with higher scores indicating greater nicotine withdrawal | 2 weeks |
| Questionnaire of Smoking Urges-Brief (QSU-Brief) | Evaluation of the craving to smoke cigarettes collected at the end of each phase for male and female participants. Range 1 to 10, with higher values indicating greater urge to smoke | 2 weeks |
| Positive and Negative Affect Scales - Positive Affect Scale (PANAS-Pos) | Evaluation of positive affect collected at the end of each phase for male and female participants. Range 10 to 50, with higher scores indicating greater positive affect | 2 weeks |
| Positive and Negative Affect Scales - Negative Affect Scale (PANAS-Neg) | Evaluation of negative affect collected at the end of each phase for male and female participants. Range 10 to 50, with higher scores indicating greater negative affect | 2 weeks |
| Smartphone Daily Measures of Nicotine Dependence Symptoms | Evaluation of mean nicotine dependence symptoms collected daily during each phase. Range 1 to 5, with higher values indicating greater nicotine dependence symptoms | 2 weeks |
| American Thoracic Society Questionnaire (ATSQ) | Evaluation of respiratory symptoms collected at the end of each phase for male and female participants. Range 8 to 40, with higher numbers indicating more respiratory symptoms | 2 weeks |
| COMPLETED |
|
| NOT COMPLETED |
|
| COMPLETED |
|
| NOT COMPLETED |
|
| Phase 1: Usual Brand Cigarette Phase (Women) |
Two weeks of smoking usual brand cigarettes followed by two weeks of using the Placebo (0% nicotine content) Standardized Research Electronic Cigarette (SREC) and the two weeks of using the Nicotine (5% nicotine content) SREC, with SREC order counterbalanced. |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
Two weeks of using the Nicotine (5% nicotine content) Standardized Research Electronic Cigarette (Men)
| OG003 | Usual Brand Cigarette Phase (Women) | Two weeks of smoking usual brand cigarettes (Women) |
| OG004 | Placebo Standardized Research Electronic Cigarette Phase (Women) | Two weeks of using the Placebo (0% nicotine content) Standardized Research Electronic Cigarette (Women) |
| OG005 | Nicotine Standardized Research Electronic Cigarette Phase (Women) | Two weeks of using the Nicotine (5% nicotine content) Standardized Research Electronic Cigarette (Women) |
|
|
| Secondary | Electronic Cigarette Sessions Per Day | Study electronic cigarette use measured by the mean number of sessions per day during each phase for male and female participants. | Electronic cigarette sessions per day were not assessed during the Usual Brand Cigarette phase. | Posted | Mean | Standard Deviation | Sessions per day | 2 weeks |
|
|
|
| Secondary | Total Nicotine Equivalents (TNE) | A measure of nicotine exposure, calculated as the sum of total nicotine, cotinine, 3'-hydroxycotinine, and nicotine N-oxide excreted in urine, collected at the end of each phase for male and female participants. | Posted | Mean | Standard Deviation | ng/mL | 2 weeks |
|
|
|
| Secondary | Anabasine | A tobacco minor alkaloid (MA) excreted in urine collected at the end of each phase for male and female participants to evaluate nicotine product exposure. | Posted | Mean | Standard Deviation | ng/mL | 2 weeks |
|
|
|
| Secondary | Nicotelline | A tobacco minor alkaloid (MA) excreted in urine collected at the end of each phase for male and female participants to evaluate nicotine product exposure. | Posted | Mean | Standard Error | ng/mL | 2 weeks |
|
|
|
| Secondary | Perceived Health Risk Questionnaire (PHRQ) | Evaluation of participants' beliefs about their risks of developing health conditions from cigarettes or electronic cigarette collected at the end of each phase for male and female participants. Range 1-10, with higher values indicating greater perceived risk of negative health outcomes. | Posted | Mean | Standard Deviation | Units on a scale | 2 weeks |
|
|
|
| Secondary | Product Evaluation Scales (PES) | Evaluation of explicit cigarette or electronic cigarette product liking collected at the end of each phase for male and female participants. Range 1-7, with higher values indicating more unpleasant ratings. | Posted | Mean | Standard Deviation | Units on a scale | 2 weeks |
|
|
|
| Secondary | Implicit Association Test (IAT) | Evaluation of implicit cigarette or electronic cigarette liking collected at the end of each phase for male and female participants. Range: -1 to 1, with more negative values indicating a more negative attitude toward the cigarette product | Posted | Mean | Standard Deviation | Units on a scale | 2 weeks |
|
|
|
| Secondary | Brief Smoking Consequences Questionnaire-Adult (BSCQ-A) | Evaluation of the perceived outcomes of cigarette or electronic cigarette use collected at the end of each phase for male and female participants. Range 0 to 9, with larger values indicating greater perceived negative consequences of cigarette use | Posted | Mean | Standard Deviation | Units on a scale | 2 weeks |
|
|
|
| Secondary | Purchase Task Breakpoint Measure | Evaluation of the Purchase Task Breakpoint measure (first price at which consumption goes to zero, i.e., unwilling to pay) for cigarettes or electronic cigarettes collected at the end of each phase for male and female participants. Range: 0.05 - 251, dollars per cigarette or per electronic cigarette puff with higher values indicating the willingness to smoke/vape at a higher price. | Posted | Mean | Standard Deviation | $/cigarette or $/e-cigarette puff | 2 weeks |
|
|
|
| Secondary | Purchase Task Demand Intensity Measure | Evaluation of the Purchase Task Demand Intensity measure (consumption at the lowest price) for cigarettes or electronic cigarettes collected at the end of each phase for male and female participants. Range: 1 - 351, the number of cigarettes or electronic cigarette puffs with higher values indicating an intension to smoke/vape more when the price is set as 0 | Posted | Mean | Standard Deviation | # of cigarettes or e-cigarette puffs | 2 weeks |
|
|
|
| Secondary | Purchase Task Omax Measure | Evaluation of the Purchase Task Omax measure (maximum financial expenditure on the product) for cigarettes or electronic cigarettes collected at the end of each phase for male and female participants. Range: 0.03 - 1001, the maximum expenditure in dollars on cigarettes or electronic cigarette puffs with higher values indicating greater expenditure | Posted | Mean | Standard Deviation | max spent $ on cigarettes or e-cig puffs | 2 weeks |
|
|
|
| Secondary | Purchase Task Pmax Measure | Evaluation of the Purchase Task Pmax measure (price at which expenditure is maximized) for cigarettes or electronic cigarettes collected at the end of each phase for male and female participants. Range: 0.01 - 1001, the price of the cigarette or electronic cigarette puffs when the Omax is reached | Posted | Mean | Standard Deviation | US Dollars per cigarette or per electron | 2 weeks |
|
|
|
| Secondary | Purchase Task Elasticity of Demand Measure | Evaluation of the Purchase Task Elasticity of Demand measure (sensitivity of product consumption to increases in cost) for cigarettes or electronic cigarettes collected at the end of each phase for male and female participants. Range: 0.0001 - 2.69, the elasticity of the demand for cigarettes or electronic cigarette puffs, with higher values indicating a greater sensitivity in reducing the consumption in response to the price increases | Posted | Mean | Standard Deviation | % change quantity/% change price | 2 weeks |
|
|
|
| Secondary | Fagerström Test for Cigarette Dependence (FTCD) | Evaluation of cigarette dependence collected at the end of each phase for male and female participants. Range 0 to 10, with higher values indicating greater cigarette dependence | Posted | Mean | Standard Deviation | Units on a scale | 2 weeks |
|
|
|
| Secondary | Penn State Electronic Cigarette Dependence Index (PSECDI) | Evaluation of electronic cigarette dependence collected at the end of each phase for male and female participants. Range 0 to 20, with higher scores indicating greater electronic cigarette dependence | The PSECDI questionnaire was not administered during the Usual Brand Cigarette phase. | Posted | Mean | Standard Deviation | Units on a scale | 2 weeks |
|
|
|
| Secondary | Minnesota Nicotine Withdrawal Scale-Revised (MNWS) | Evaluation of nicotine withdrawal symptoms collected at the end of each phase for male and female participants. Range 0 to 60, with higher scores indicating greater nicotine withdrawal | Posted | Mean | Standard Deviation | Units on a scale | 2 weeks |
|
|
|
| Secondary | Questionnaire of Smoking Urges-Brief (QSU-Brief) | Evaluation of the craving to smoke cigarettes collected at the end of each phase for male and female participants. Range 1 to 10, with higher values indicating greater urge to smoke | Posted | Mean | Standard Deviation | Units on a scale | 2 weeks |
|
|
|
| Secondary | Positive and Negative Affect Scales - Positive Affect Scale (PANAS-Pos) | Evaluation of positive affect collected at the end of each phase for male and female participants. Range 10 to 50, with higher scores indicating greater positive affect | Posted | Mean | Standard Deviation | Units on a scale | 2 weeks |
|
|
|
| Secondary | Positive and Negative Affect Scales - Negative Affect Scale (PANAS-Neg) | Evaluation of negative affect collected at the end of each phase for male and female participants. Range 10 to 50, with higher scores indicating greater negative affect | Posted | Mean | Standard Deviation | Units on a scale | 2 weeks |
|
|
|
| Secondary | Smartphone Daily Measures of Nicotine Dependence Symptoms | Evaluation of mean nicotine dependence symptoms collected daily during each phase. Range 1 to 5, with higher values indicating greater nicotine dependence symptoms | Posted | Mean | Standard Deviation | Units on a scale | 2 weeks |
|
|
|
| Secondary | American Thoracic Society Questionnaire (ATSQ) | Evaluation of respiratory symptoms collected at the end of each phase for male and female participants. Range 8 to 40, with higher numbers indicating more respiratory symptoms | Posted | Mean | Standard Deviation | Units on a scale | 2 weeks |
|
|
|
| 0 |
| 87 |
| 0 |
| 87 |
| 0 |
| 87 |
| EG001 | Placebo Standardized Research Electronic Cigarette Phase (Men) | Two weeks of using the Placebo (0% nicotine content) Standardized Research Electronic Cigarette (Men) | 0 | 87 | 1 | 87 | 0 | 87 |
| EG002 | Nicotine Standardized Research Electronic Cigarette Phase (Men) | Two weeks of using the Nicotine (5% nicotine content) Standardized Research Electronic Cigarette (Men) | 0 | 87 | 3 | 87 | 0 | 87 |
| EG003 | Usual Brand Cigarette Phase (Women) | Two weeks of smoking usual brand cigarettes (Women) | 0 | 82 | 1 | 82 | 0 | 82 |
| EG004 | Placebo Standardized Research Electronic Cigarette Phase (Women) | Two weeks of using the Placebo (0% nicotine content) Standardized Research Electronic Cigarette (Women) | 0 | 82 | 1 | 82 | 0 | 82 |
| EG005 | Nicotine Standardized Research Electronic Cigarette Phase (Women) | Two weeks of using the Nicotine (5% nicotine content) Standardized Research Electronic Cigarette (Women) | 0 | 82 | 2 | 82 | 0 | 82 |
| Dyspnea | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Flu Like Symptoms | General disorders | Systematic Assessment |
|
| Gastrointestinal Disorders - Other | Gastrointestinal disorders | Systematic Assessment |
|
| Psychosis | Nervous system disorders | Systematic Assessment |
|
| Upper Respiratory Infection | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
Not provided
Not provided
Not provided